ARTL - Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany | Benzinga
SOLANA BEACH, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced George Warren, PhD., Principal Scientist at Artelo Biosciences, will be presenting new preclinical data on ART12.11, the Company's proprietary cocrystal of cannabidiol (CBD) and tetremethylpyrazine (TMP), at the 4th Annual Med-Cannabis 2023 conference being held December 4-5, 2023 in Frankfurt, Germany.
"We are pleased to be presenting important new preclinical data at this international event," commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. "Cocrystalization is a validated pharmaceutical method for improving a drug's physiochemical properties and we believe this preclinical data further demonstrates the potential of ART12.11 to be a market leading treatment for anxiety and other areas where CBD has demonstrated clinical benefit."
About ART12.11
ART12.11 is a proprietary cocrystal composition of cannabidiol (CBD). It is isolated as a single crystalline form that offers biopharmaceutic advantages over compositions of CBD that exhibit solid polymorphism (i.e., the ...